| 0 | 💬 0 |
Phase 1, first-in-human, randomized, placebo-controlled, dose-escalating study to evaluate OVX033, a nucleocapsid-based SARS-CoV-2 candidate vaccine.
(academic.oup.com)
|
Journal of Infectious Diseases 2026-08-12 | #covid-19 #vaccination #immunogenicity #clinical trial #safety |